李雨夏,郑红宾

弥漫性毒性甲状腺肿,即Graves病（GD）是甲状腺功能亢进症（甲亢）的主要类型。放射性碘131（131I）治疗凭借其疗效确切、操作简便的优势成为临床一线治疗方案，但疗效存在显著个体差异。现有指标预测131I治疗效果有限，需挖掘可靠的疗效预测指标指导临床决策。甲状腺血管杂音是GD患者甲状腺高代谢状态特征性体征之一，而彩色多普勒血流显像检测的甲状腺上动脉收缩期峰值流速是反映甲状腺血流动力学异常的关键量化指标。本文回顾多项研究，就血流动力学指标在131I治疗GD中的研究进展作一综述。

Graves病；碘131治疗；血流动力学；血管杂音；收缩期峰值流速

[1] LEE S Y,PEARCE E N.Hyperthyroidism:A Review[J].JAMA,2023,330(15):1472-1483. [2] LI Y,TENG D,BA J,et al.Efficacy and Safety of Long-Term Universal Salt Iodization on Thyroid Disorders:Epidemiological Evidence from 31 Provinces of Mainland China[J].Thyroid®,2020,30(4):568-579. [3] SANTOS T A R R,MARUI S,WATANABE T,et al.Color Duplex Doppler US can Follow up the Response of Radioiodine in Graves'Disease by Evaluating the Thyroid Volume and Peak Systolic Velocity[J].Ultraschall Med,2020,41(6):658-667. [4] 刘光清,黄利,郑海龙,等.甲状腺上动脉血流速度改变对药物治疗甲亢复发的预测价值[J].海南医学院学报,2018,24(05):647-650. [5] 杨思光,林少梅.甲状腺上动脉峰值血流速度在鉴别妊娠期甲状腺功能亢进和妊娠合并Graves病中的价值[J].中国医药科学,2017,7(13):235-237. [6] 檀谊洪,杜国能,陈庞州,等.甲状腺上动脉峰值流速与Graves病甲状腺切除术中出血量的相关性研究[J].中国全科医学,2013, 16(14):1224-1227. [7] HARUN-OR-RASHID M,ASAI M,SUN X,et al.Effect of thyroid statuses on sodium/iodide symporter(NIS)gene expression in the extrathyroidal tissues in mice[J].Thyroid Res,2010,3(1):3. [8] CAMPENNÌA,AVRAM A M,VERBURG F A,et al.The EANM guideline on radioiodine therapy of benign thyroid disease[J].Eur J Nucl Med Mol Imaging,2023,50(11):3324-3348. [9] BARTALENA L,GALLO D,KAHALY G J,et al.Process to radioactive iodine treatment for Graves'hyperthyroidism:condemned or absolved?[J].J Endocrinol Invest,2025,48(9):1927-1950. [10] 蒙福卿.育龄女性甲亢患者碘-131治疗前后血清性激素水平及生育随访分析[J].世界复合医学,2019,5(02):23-25. [11] RON E,DOODY M M,BECKER D V,et al.Cancer mortality following treatment for adult hyperthyroidism.Cooperative Thyrotoxicosis Therapy Follow-up Study Group[J].JAMA,1998,280(4):347-355. [12] MOMO H D,HAYMART M R,SHI X,et al.Associations Between Radioactive Iodine Treatment for Hyperthyroidism and Cancer Incidence and Mortality[J].J Clin Endocrinol Metab,2026. [13] WIERSINGA W M,POPPE K G,EFFRAIMIDIS G.Hyperthyroidism:aetiology,pathogenesis,diagnosis,management,complications,and prognosis[J].Lancet Diabetes Endocrinol,2023,11(4):282-298. [14] de OLIVEIRA MACENA LÔBO A,SOBREIRA L E R,RIBEIRO D M,et al.Comparison of mortality and cardiovascular morbidity following treatment for hyperthyroidism:A systematic review and bayesian network meta-analysis[J].Endocrine,2025,90(1):39-48. [15] WATANABE N.A narrative review of long-term inorganic iodine monotherapy for Graves'disease with a historical relationship between iodine and thyroid[J].Endocr J,2025,72(1):23-36. [16] DIETLEIN M,GRÜNWALD F,SCHMIDT M,et al.[Guideline for Radioiodine Therapy for Benign Thyroid Diseases(6/2022-AWMF No.031-003)][J].Nuklearmedizin,2024,63(1):8-20. [17] 马子宇,李雪,王岩,等.^(131)I治疗格雷夫斯病疗效的影响因素分析及疗效预测[J].中华核医学与分子影像杂志,2025, 45(1):24-28. [18] 姚晓波,肖林林,卞岍雨,等.^(131)I治疗Graves甲亢伴中性粒细胞减少的疗效分析[J].安徽医科大学学报,2022,57(5):823-827. [19] 喻晖,齐佳,颜喻.放射性核素131碘治疗老年甲状腺功能亢进症的安全性和有效性[J].贵州医科大学学报,2021,46(03):357-361. [20] 董佳佳,章斌,韩江琴,等.131Ⅰ治疗合并肝损害Graves甲亢的疗效分析[J].标记免疫分析与临床,2020,27(12):2063-2066. [21] NAGURA S,KATOH R,MIYAGI E,et al.Expression of vascular endothelial growth factor(VEGF)and VEGF receptor-1(Flt-1)in Graves disease possibly correlated with increased vascular density[J].Hum Pathol,2001,32(1):10-17. [22] SATO K,YAMAZAKI K,SHIZUME K,et al.Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo[J].J Clin Invest,1995,96(3):1295-1302. [23] RAMSDEN J D.Angiogenesis in the thyroid gland[J].J Endocrinol,2000,166(3):475-480. [24] 张丕玉.甲状腺血管杂音听诊在甲亢病诊断中的价值[J].中国现代药物应用,2009,3(08):159. [25] 徐乐超,杨临洪.Graves病患者甲状腺区杂音及相关因素分析[J].哈尔滨医药,2005(02):29-30. [26] 莫李生.甲状腺血供与甲状腺疾病临床表现的关系[J].广东医学,2000(05):416-417. [27] 蒙碧辉,冼苏,罗佐杰.甲状腺机能亢进症股动脉枪击音和甲状腺血管杂音临床对照研究[J].临床医学,1998(01):27-28. [28] 廖国荣,游钜鸿,潘百思.甲状腺血管杂音对甲状腺功能亢进诊断的价值(附500例临床分析)[J].广东医学,1992(05):238-239. [29] 刘慧珍,史育红,江雪,等.碘131治疗甲状腺功能亢进症效果影响因素分析[J].预防医学情报杂志,2020,36(07):933-939. [30] 徐琳琳.彩色多普勒超声检查诊断甲状腺疾病影像学表现及临床诊断效果[J].影像研究与医学应用,2025,9(06):75-77. [31] LI S,DING Z,LI X,et al.A meta-analysis:elucidating diagnostic thresholds of peak systolic flow velocities in thyroid arteries for the discrimination of Graves'disease and destructive thyrotoxicosis[J].Front Endocrinol(Lausanne),2024,15:1393126. [32] 刘巧珍,唐英杰,曲琨,等.甲状腺超声对亚急性甲状腺炎的临床诊断价值[J].影像研究与医学应用,2024,8(13):132-134. [33] 宋晨.彩色多普勒超声对甲亢患者甲状腺血流分级的评估价值及与甲状腺激素的相关性[J].实用医学影像杂志,2024,25(01):21-24. [34] 张玲云,张国全,贾涛,等.彩色多普勒超声对甲亢患者甲状腺血流分级与功能指标的关系研究[J].医学影像学杂志,2020, 30(08):1357-1360. [35] 汤彪,柯章明,孙圣荣.甲状腺上动脉峰值流速与Graves病患者甲状腺激素水平及术中出血量关系的研究[J].临床和实验医学杂志,2014,13(05):373-376. [36] 王井,卢小燕,韦一和.甲状腺上动脉峰值流速与甲状腺功能亢进症治疗前后甲状腺激素水平的关系[J].实用医技杂志,2011, 18(08):803-804. [37] 冯新嫄,孙慧洁,刘天赐,等.超声对Graves病孕妇治疗过程中胎儿甲状腺异常早期诊断和监测的价值[J].临床医学研究与实践, 2025,10(10):98-101. [38] 史亚婷.超声在甲状腺疾病诊断中的应用[J].人人健康,2025(28):112-113. [39] 雷劲松.彩色多普勒超声诊断与鉴别亚急性甲状腺炎的应用价值[J].数理医药学杂志,2020,33(08):1130-1132. [40] 董理聪,韩燕妮.甲状腺上动脉超声检查在甲状腺弥漫性病变的诊断价值[J].影像研究与医学应用,2019,3(14):166-167. [41] 梁昌平,李隆敏,田小雪,等.首次^(131)I治疗前TPOAb､TgAb及TRAb状态对Graves病患者治疗后甲状腺功能减退的预测价值[J].中华内分泌代谢杂志,2024,40(8):676-680. [42] 谢志君,犹真明,李立,等.TPO-Ab､TgAb､TRAb在判定^(131)I治疗格雷夫斯甲亢患者转归中的预示性价值[J].四川医学,2019, 40(2):117-120.

点击下载PDF